IDDI at the 5th Annual Next Gen Immuno-Oncology Virtual Congress
October 26, 2021 — October 29, 2021
Join IDDI’s team at the 5th Annual Next Gen Immuno-Oncology Virtual Congress from 26-29 October 2021!
The Congress would address the challenges and future directions in IO research. It aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitor.
WEBINAR ASSESSING TREATMENT BENEFIT IN IMMUNO-ONCOLOGY
On October 26, 17:45 – 18:15 (CET): A webinar entitled ASSESSING TREATMENT BENEFIT IN IMMUNO-ONCOLOGY will be run by Laurence Collette, MSc, PhD, Principal Statistician, Consulting Services at IDDI
In this presentation, Dr. Collette will discuss the immune response criteria and elaborate the quantifying benefits when the effect is non-proportional. She will also provide considerations for study monitoring.
IDDI’s Experts will be available to discuss the challenges and see how we can assist with your future clinical trial development plans!
SCHEDULE A MEETING today by contacting Vicky Martin, IDDI’s Senior Director of Business Development US at email@example.com or Robert Whitaker, IDDI Director, Business Development, West Coast USA at firstname.lastname@example.org